Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome

Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · Nov 5, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called epcoritamab for patients with chronic lymphocytic leukemia (CLL) and Richter syndrome, which is a type of aggressive cancer that can occur in people with CLL. The goal of the study is to learn how this treatment works in the body by collecting and analyzing samples from participants. These samples will be taken from lymph nodes, bone marrow, and blood at different times during the treatment to see how the disease and the body’s immune response change.

To be eligible for this study, participants must be undergoing screening for another related study called GCT3013-03 and must be willing to follow all study procedures. There are no specific exclusions based on health conditions. Participants can expect to provide samples and receive careful monitoring throughout the treatment period. This research is important because it will help improve our understanding of epcoritamab and its potential as a new type of cancer therapy that helps the immune system fight cancer more effectively.

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• In order to be eligible to participate in this study, an individual must meet all of the following criteria:
• • Must be undergoing screening for GCT3013-03
• • Stated willingness to comply with all study procedures and availability for the duration of the study
• • Ability of subject to understand and the willingness to sign a written informed consent document.
• EXCLUSION CRITERIA:
• • None